Delayed Clinical Response in Patients with Juvenile Idiopathic Arthritis Treated with Etanercept

REFERENCES

1. 1.↵
   1. Lovell DJ,
   2. Giannini EH,
   3. Reiff A,
   4. Cawkwell GD,
   5. Silverman ED,
   6. Nocton JJ,
   7. et al.

   Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Lovell DJ,
   2. Reiff A,
   3. Ilowite NT,
   4. Wallace CA,
   5. Chon Y,
   6. Lin SL,
   7. et al.

   Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496–504.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Prince FH,
   2. Twilt M,
   3. ten Cate R,
   4. van Rossum MA,
   5. Armbrust W,
   6. Hoppenreijs EP,
   7. et al.

   Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2008;68:635–41.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Horneff G,
   2. Schmeling H,
   3. Biedermann T,
   4. Foeldvari I,
   5. Ganser G,
   6. Girschick HJ,
   7. et al.

   The German etanercept registry for treatment of juvenile idiopathic arthritis. Ann Rheum Dis 2004;63:1638–44.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328–46.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Furst DE,
   2. Breedveld FC,
   3. Kalden JR,
   4. Smolen JS,
   5. Burmester GR,
   6. Sieper J,
   7. et al.

   Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66 Suppl 3:iii2–22.

   OpenUrlFREE Full Text
7. 7.↵
   1. National Institute for Clinical Excellence

   . Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. Technology Appraisal No. 35. [Internet. Accessed November 26, 2009.] Available from: http://guidance.nice.org.uk/TA35/Guidance/pdf/English
8. 8.↵
   1. Kavanaugh A,
   2. Klareskog L,
   3. van der Heijde D,
   4. Li J,
   5. Freundlich B,
   6. Hooper M

   . Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. Ann Rheum Dis 2008;67:1444–7.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Kievit W,
   2. Fransen J,
   3. Adang EM,
   4. Kuper HH,
   5. Jansen TL,
   6. De Gendt CM,
   7. et al.

   Evaluating guidelines of continuation of anti-TNF treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies. Ann Rheum Dis 2008;68:844–9.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Pocock JM,
    2. Vasconcelos JC,
    3. Ostor AJ

    . Assessment of anti-TNF-alpha efficacy in rheumatoid arthritis: is 3 months sufficient? Rheumatology 2008;47:1073–6.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Lovell DJ,
    2. Giannini EH,
    3. Reiff A,
    4. Jones OY,
    5. Schneider R,
    6. Olson JC,
    7. et al.

    Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48:218–26.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Prince FH,
    2. Ferket IS,
    3. Kamphuis S,
    4. Armbrust W,
    5. ten Cate R,
    6. Hoppenreijs EP,
    7. et al.

    Development of a web-based register for the Dutch national study on biologicals in JIA: www.ABC-register.nl. Rheumatology 2008;47:1413–6.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Giannini EH,
    2. Ruperto N,
    3. Ravelli A,
    4. Lovell DJ,
    5. Felson DT,
    6. Martini A

    . Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.

    OpenUrlPubMed
14. 14.↵
    1. Wallace CA,
    2. Ruperto N,
    3. Giannini E

    . Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004;31:2290–4.

    OpenUrlAbstract/FREE Full Text